% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{HuynhLe:156801,
      author       = {M.-P. Huynh-Le and C. C. Fan and R. Karunamuni and E. I.
                      Walsh and E. L. Turner and J. A. Lane and R. M. Martin and
                      D. E. Neal and J. L. Donovan and F. C. Hamdy and J. K. K.
                      Parsons and R. A. Eeles and D. F. Easton and Z. Kote-Jarai
                      and A. Amin Al Olama and S. Benlloch Garcia and K. Muir and
                      H. Grönberg and F. Wiklund and M. Aly and J. Schleutker and
                      C. Sipeky and T. Tammela and B. G. Nordestgaard and T. J.
                      Key and R. C. Travis and P. D. P. Pharoah and N. Pashayan
                      and K.-T. Khaw and S. N. Thibodeau and S. K. McDonnell and
                      D. J. Schaid and C. Maier and W. Vogel and M. Luedeke and K.
                      Herkommer and A. S. Kibel and C. Cybulski and D. Wokolorczyk
                      and W. Kluzniak and L. A. Cannon-Albright and H. Brenner$^*$
                      and B. Schöttker$^*$ and B. Holleczek and J. Y. Park and T.
                      A. Sellers and H.-Y. Lin and C. K. Slavov and R. P. Kaneva
                      and V. I. Mitev and J. Batra and J. A. Clements and A. B.
                      Spurdle and M. R. Teixeira and P. Paulo and S. Maia and H.
                      Pandha and A. Michael and I. G. Mills and O. A. Andreassen
                      and A. M. Dale and T. M. Seibert},
      title        = {{A} genetic risk score to personalize prostate cancer
                      screening, applied to population data.},
      journal      = {Cancer epidemiology, biomarkers $\&$ prevention},
      volume       = {29},
      number       = {9},
      issn         = {1538-7755},
      address      = {Philadelphia, Pa.},
      publisher    = {AACR},
      reportid     = {DKFZ-2020-01118},
      pages        = {1731-1738},
      year         = {2020},
      note         = {2020 Sep;29(9):1731-1738},
      abstract     = {A polygenic hazard score (PHS)-the weighted sum of 54 SNP
                      genotypes-was previously validated for association with
                      clinically significant prostate cancer and for improved
                      prostate cancer screening accuracy. Here, we assess the
                      potential impact of PHS-informed screening.UK population
                      incidence data (Cancer Research UK) and data from the
                      Cluster Randomized Trial of PSA Testing for Prostate Cancer
                      were combined to estimate age-specific clinically
                      significant prostate cancer incidence (Gleason≥7, stage
                      T3-T4, PSA ≥10, or nodal/distant metastases). Using hazard
                      ratios estimated from the ProtecT prostate cancer trial,
                      age-specific incidence rates were calculated for various PHS
                      risk percentiles. Risk-equivalent age-when someone with a
                      given PHS percentile has prostate cancer risk equivalent to
                      an average 50-year-old man (50-years-standard risk)-was
                      derived from PHS and incidence data. Positive predictive
                      value (PPV) of PSA testing for clinically significant
                      prostate cancer was calculated using PHS-adjusted age
                      groups.The expected age at diagnosis of clinically
                      significant prostate cancer differs by 19 years between the
                      1st and 99th PHS percentiles: men with PHS in the 1st and
                      99th percentiles reach the 50-years-standard risk level at
                      ages 60 and 41, respectively. PPV of PSA was higher for men
                      with higher PHS-adjusted age.PHS provides individualized
                      estimates of risk-equivalent age for clinically significant
                      prostate cancer. Screening initiation could be adjusted by a
                      man's PHS.Personalized genetic risk assessments could inform
                      prostate cancer screening decisions.},
      cin          = {C070 / C120 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)C120-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32581112},
      doi          = {10.1158/1055-9965.EPI-19-1527},
      url          = {https://inrepo02.dkfz.de/record/156801},
}